6/12
06:32 am
ngne
Neurogene Inc. (NASDAQ: NGNE) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Neutral
Report
Neurogene Inc. (NASDAQ: NGNE) was upgraded by analysts at Baird R W to a "strong-buy" rating.
6/11
07:31 am
ngne
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $54.00 price target on the stock.
Low
Report
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $54.00 price target on the stock.
6/5
07:30 am
ngne
Neurogene to Participate in Upcoming Conferences
Low
Report
Neurogene to Participate in Upcoming Conferences
6/4
08:04 am
ngne
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Low
Report
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
6/3
07:39 am
ngne
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program [Yahoo! Finance]
Low
Report
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program [Yahoo! Finance]
6/3
07:30 am
ngne
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
Low
Report
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
5/13
11:22 am
ngne
Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $51.00. They now have a "buy" rating on the stock.
Medium
Report
Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $51.00. They now have a "buy" rating on the stock.
5/10
07:30 am
ngne
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
Low
Report
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
5/7
06:35 am
ngne
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting [Yahoo! Finance]
Low
Report
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting [Yahoo! Finance]
5/7
06:19 am
ngne
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
Low
Report
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
5/3
05:06 pm
ngne
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Medium
Report
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
5/1
07:37 am
ngne
Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
4/29
08:18 am
ngne
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $46.00 price target on the stock.
High
Report
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $46.00 price target on the stock.
4/22
04:46 pm
ngne
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting [Yahoo! Finance]
Low
Report
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting [Yahoo! Finance]
4/22
04:36 pm
ngne
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
Low
Report
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
3/26
02:18 pm
ngne
Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers [Seeking Alpha]
Low
Report
Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers [Seeking Alpha]
3/21
08:06 am
ngne
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Medium
Report
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
3/19
08:09 am
ngne
Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at HC Wainwright from $45.00 to $55.00. They now have a "buy" rating on the stock.
High
Report
Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at HC Wainwright from $45.00 to $55.00. They now have a "buy" rating on the stock.
3/19
07:17 am
ngne
With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors [Yahoo! Finance]
High
Report
With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors [Yahoo! Finance]
3/18
04:20 pm
ngne
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates [Yahoo! Finance]
High
Report
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates [Yahoo! Finance]
3/18
04:14 pm
ngne
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
High
Report
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates